Screener
Amneal Pharmaceuticals, Inc. AMRX Subtotal dosage forms — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Biosimilar | 29,128 | 25,248 | 51,429 | 53,788 |
| Oral liquid | 10,371 | 17,879 | 22,463 | 41,427 |
| Other dosage forms (1) | 81,594 | 68,185 | 128,206 | 124,607 |
| Subtotal dosage forms | 482,300 | 431,524 | 900,218 | 844,998 |
| International | 7,613 | 1,901 | 12,932 | 3,135 |
| Total Affordable Medicines net revenue | 489,913 | 433,425 | 913,150 | 848,133 |
| Specialty | ||||
| Central nervous system | 95,344 | 83,425 | 178,727 | 151,035 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported subtotal dosage forms — net revenue of $482.3M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue increased by 11.8% year-over-year, from $431.52M to $482.3M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue has grown at a 6.8% compound annual growth rate (CAGR), from $1.42B to $1.73B.
- What does subtotal dosage forms — net revenue mean?
- This metric represents the total gross sales generated from a specific category of pharmaceutical product delivery systems, adjusted for returns, allowances, and discounts. It serves as a key indicator of the market demand and commercial performance for the company's diverse portfolio of dosage forms. Tracking this revenue stream helps investors evaluate the segment's contribution to overall top-line growth and its competitive positioning within the broader generics market.
Ask your AI about Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude